Andrx changing Altocor name
Executive Summary
Andrx is in discussions with FDA to market Altocor (lovastatin extended-release) under a new name "to avoid possible confusion in the marketplace." Company says name change is unrelated to Kos' lawsuit alleging a likelihood of confusion with its cholesterol-lowering agent Advicor (niacin/lovastatin). FDA already has approved Altoprev as an alternative brand for Altocor (1"The Pink Sheet" Sept. 15, 2003, In Brief)...
You may also be interested in...
Kos settles Advicor name dispute with Andrx
Andrx will end use of the Altocor name and pay $6 mil. to settle trademark dispute over Kos' cholesterol product Advicor. Settlement ends litigation in Philadelphia federal appeals court. Kos' original complaint in New Jersey federal court sought to enjoin Andrx from using Altocor name for its extended-release lovastatin; that motion was denied. Andrx will now market its product as Altoprev, a name approved by FDA in August 2003 (1"The Pink Sheet" May 10, 2004, In Brief)...
Andrx considers Altocor name change
Andrx is considering changing the name of the extended-release statin Altocor (lovastatin) to Altoprev. FDA approved the name Altoprev in an Aug. 20 1letter. Andrx submitted the sNDA with the proposed name change Dec. 5, 2002...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”